Establishing Clinical Utility Evidence to Support Coverage and Reimbursement for Venn Biosciences' Dawn Test

QURE will use its CPV technology in a randomized controlled trial to measure how InterVenn Biosciences diagnostic test changes clinical practice and improves patient outcomes.

Inclusion Criteria:Board-certified medical oncologists for at least two yearsAveraging at least 20 hours per week of clinical and patient care duties over the last six monthsRoutinely evaluate patients with advanced/metastatic NSCLC in their practicePrescribe IO therapies for their advanced/metastatic NSCLC patientsPractice in either an academic, non-academic, or network hospital settingPracticing in the U.S.English speakingAccess to the internetInformed, signed, and voluntarily consented to be in the studyExclusion Criteria:Not board-certified in oncologyNot English speakingNot averaging at least 20 hours per week of clinical and patient care duties over the last six monthsNot practicing in the U.S.No access to the internetDid not voluntarily consent to be in the study